Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Sibel Tekin"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
We evaluated elagolix and leuprolide from the patient’s perspective for the treatment of endometriosis-related pain. Preference weights from a published discrete choice experiment were used to evaluate preferences for treatment profiles simulating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9c476b9a9a526e607a3f77fad5960c
Publikováno v:
Bilge International Journal of Science and Technology Research. 2:147-156
Yaban hayatı türlerine yönelik koruma ve yönetim çalışmalarının etkin bir şekilde gerçekleştirilebilmesi için türlerin kullandığı habitat büyüklüklerinin belirlenmesi, habitat tercihlerinde rol oynayan değişkenlerin tespit edilm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e446ecdf1b22f1c58496f3dd4b5e359c
https://doi.org/10.30516/bilgesci.399017
https://doi.org/10.30516/bilgesci.399017
Autor:
Esenboğa, Kerim, Kurtul, Alparslan, Nazman, Hüseyin, Tekin, Cemre Gül, Özyüncü, Nil, Tan, Türkan Seda, Tutar, Eralp, Turhan, Sibel Tekin
Publikováno v:
Angiology; Jan2022, Vol. 73 Issue 1, p73-78, 6p
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 25:627-633
Alzheimer’s disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1310c53c9529b34ac5cb5c0bd5631fb7
https://doi.org/10.1177/1533317510385808
https://doi.org/10.1177/1533317510385808
Publikováno v:
CNS Neuroscience & Therapeutics. 16:330-336
SUMMARY Background and objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ff80db36c197bb5ef65745850dc8702
https://doi.org/10.1111/j.1755-5949.2010.00182.x
https://doi.org/10.1111/j.1755-5949.2010.00182.x
Autor:
Frederick A. Schmitt, Sibel Tekin, Kolbjørn Brønnick, Dag Aarsland, Xiangyi Meng, Jason T. Olin
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 25:407-413
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) items wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4436415208d78df86249df85898dc86
https://doi.org/10.1177/1533317510367486
https://doi.org/10.1177/1533317510367486
Publikováno v:
Turk Dermatoloji Dergisi, Vol 03, Iss 04, Pp 93-96 (2009)
Turk Dermatoloji Dergisi, Vol 3, Iss 4, Pp 93-96 (2009)
Turk Dermatoloji Dergisi, Vol 3, Iss 4, Pp 93-96 (2009)
A nine-year old girl admitted to our clinic with two months history of itchy skin eruption, initially started on the arms and then disseminated to all the body including the face. Dermatological examination revealed extensive papulosquamous lesions c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::03e0ab86f4a69c5b509c1ec608a2d7de
http://www.turkdermatolojidergisi.com/yazilar.asp?yaziid=88&sayiid=
http://www.turkdermatolojidergisi.com/yazilar.asp?yaziid=88&sayiid=
Autor:
Chuanchieh Hsu, Roger Lane, Philip D. Harvey, Sibel Tekin, Steven H. Ferris, Jeffrey L. Cummings, Keith Wesnes
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 25:142-148
Disease-specific assessments are not currently available for patients with Parkinson’s disease dementia (PDD). This study evaluated the criterion-related validity and test—retest reliability of the Alzheimer’s Disease Assessment scale cognitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2c2e773cb8e75cd7d86ea41926e8cd2
https://doi.org/10.1177/1533317509333904
https://doi.org/10.1177/1533317509333904
Autor:
Jennifer Nagel, Jacqueline Ros, Sibel Tekin, Lutz Frölich, Stefanie Zechner, Jean-Marc Orgogozo, George T. Grossberg, Hans Förstl, Carl H. Sadowsky
Publikováno v:
ResearcherID
The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191518aa610fe37686348a60a6d5aab9
https://doi.org/10.1097/wad.0b013e31818b1c2c
https://doi.org/10.1097/wad.0b013e31818b1c2c